

Date: 9<sup>th</sup> May, 2024

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001  
Scrip Code: 533573

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: APLLTD

Dear Sir/Madam,

**Sub: Press Release on the Audited Financial Results for the quarter and Financial Year ended 31<sup>st</sup> March, 2024.**

With reference to the captioned subject, please find enclosed herewith Press Release on the Audited Financial Results for the quarter and financial year ended 31<sup>st</sup> March, 2024.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Alembic Pharmaceuticals Limited**

**Manisha Saraf**  
**Company Secretary**

Encl.: A/a.

**Press Release**

**PBT up 57% to Rs. 183 Crores for the Quarter**

**PBT up 78% to Rs. 632 Crores for the year**

**Vadodara, May 9<sup>th</sup>, 2024**

Alembic Pharmaceuticals Limited reported its consolidated financial results for the four quarter and year ended 31<sup>st</sup> March, 2024.

**Financial Highlights**

**For the Quarter**

- Net Sales increased 8% to Rs.1517 Crores.
- Net Profit up 17% to Rs.178 Crores
- EBITDA up 29% to Rs. 263 Crores.

**For the Year**

- Net Sales grew 10% to Rs.6229 Crores.
- Net Profit up 80% to Rs.616 Crores
- EBITDA up 41% to Rs. 961 Crores.

**Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited said** “India Branded Business continues to work on improving the execution ability both in quality & scale. The Specialty and Animal health segment witnessed robust growth. The outlook for the US business appears better, with the commercialization of new facilities and launches set to scale up along with continued progress in achieving cost improvements. The Ex-US generics and the API business maintained a steady continuous growth.”

**Operational Highlights**

**India Branded Business**

- India Branded Business grew 3% to Rs. 503 crores for the quarter and grew 7% for the year to Rs. 2,200 cr.
- Witnessed healthy growths in Gynecology, Gastrointestinal, Anti Diabetic and Ophthalmology therapies as compared to market growth for the quarter and year.
- Relative degree of performance continues to be in line with market for Antibiotic and Respiratory segments despite high base of previous year.
- Animal Health business grew 34% for the quarter and 27% for the year. Basket of strong brands continue to drive outperformance.

**ALEMBIC PHARMACEUTICALS LIMITED**

### International Business

- US Generics grew 19% to Rs. 423 Crores for the quarter.
- 7 Launches in the US market in Q4
- Ex-US International Formulations grew 5% to Rs. 262 Crores for the quarter.
- 197 Cumulative ANDA approvals.

### API Business

- API business grew 5% to Rs. 330 Crores for the quarter.

The summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q4 FY24	Q4 FY23	% Change	FY24	FY23	% Change
<b>Formulation</b>						
India	503	490	3%	2200	2063	7%
USA	423	354	19%	1730	1572	10%
Ex- US	262	249	5%	1052	852	23%
<b>API</b>	330	313	5%	1246	1166	7%
<b>Total</b>	<b>1517</b>	<b>1406</b>	<b>8%</b>	<b>6229</b>	<b>5653</b>	<b>10%</b>

### About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5000 are well recognized by doctors and patients.

Information about the company can be found at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com);  
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

### For more information contact:

<b>Ajay Kumar Desai</b> <b>Phone: +91 022- 66953681</b> <b>Email: <a href="mailto:ajay.desai@alembic.co.in">ajay.desai@alembic.co.in</a></b>	<b>Mitanshu Shah</b> <b>Phone: +91 265 – 6637630</b> <b>Email: <a href="mailto:mitanshu.shah@alembic.co.in">mitanshu.shah@alembic.co.in</a></b>
--	---

### **ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229  
 Website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123